Poly(lactic acid) nanoparticles of the lead anticancer ruthenium compound KP1019 and its surfactant-mediated activation.

Nanoparticle formulations offer besides the advantage of passive drug targeting also the opportunity to increase the stability of drugs. KP1019 is a lead ruthenium(III) compound which has been successfully tested in a clinical phase I trial. However, it is characterized by low stability in aqueous solution especially at physiological pH. To overcome this limitation, poly(lactic acid) (PLA) nanoparticles of KP1019 with two different surfactants (Pluronic F68 and Tween 80) were prepared by a single oil-in-water (o/w) emulsion. Cytotoxicity measurements comparing different aged Tween 80 nanoparticles revealed that the color change from brown to green was associated with an up to 20 fold increased activity compared to "free" KP1019. Further investigations suggested that this is based on the formation of enhanced intracellular reactive oxygen species levels. Additional studies revealed that the origin of the green color is a reaction between KP1019 and Tween 80. Kinetic studies of this reaction mixture using UV-Vis, ESI-MS and ESR spectroscopy indicated on the one hand a coordination of Tween 80 to KP1019, and on the other hand, the color change was found to correlate with a reduction of the Ru(III) center by the surfactant. Together, the results provide a first experimental approach to stabilize a biologically active Ru(II) species of KP1019 in aqueous solution, which probably can be also used to selectively generate this activated species in the tumor tissue via delivery of KP1019 using Tween 80 nanoparticles.

• Publication year

  2014

• Venue

  Dalton Transactions

• Publication date

  2014-01-21

• Fields of study

  Medicine, Materials Science, Chemistry

• Identifiers
  DOI 10.1039/c3dt52388hPMID 24165902
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Biomaterials

  2020cited by this paper
• Biomedical detection via macro- and nano-sensors fabricated with metallic and semiconducting oxides.

  2013cited by this paper
• Bulky N(,N)-(di)alkylethane-1,2-diamineplatinum(II) compounds as precursors for generating unsymmetrically substituted platinum(IV) complexes.

  2013cited by this paper
• The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo.

  2013cited by this paper
• Redox activation of metal-based prodrugs as a strategy for drug delivery.

  2012cited by this paper
• Effects of surfactants on the properties of PLGA nanoparticles.

  2012cited by this paper
• Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates.

  2012cited by this paper
• Influence of ascorbic acid on the activity of the investigational anticancer drug KP1019

  2011cited by this paper
• Anticancer Activity of Metal Complexes: Involvement of Redox Processes

  2011cited by this paper
• Serum-protein interactions with anticancer Ru(III) complexes KP1019 and KP418 characterized by EPR

  2010cited by this paper
• Surface modification of PLGA nanospheres with Gd-DTPA and Gd-DOTA for high-relaxivity MRI contrast agents.

  2010cited by this paper
• Colloidal nanocarriers: a review on formulation technology, types and applications toward targeted drug delivery.

  2010cited by this paper
• Ruthenium-based chemotherapeutics: are they ready for prime time?

  2010cited by this paper
• Nanotechnology olymer-based nanocapsules for drug delivery

  2009cited by this paper
• Electron-transfer activated metal-based anticancer drugs

  2008cited by this paper
• Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: structure and degradation pathways.

  2008cited by this paper
• Analysis of DHE-derived oxidation products by HPLC in the assessment of superoxide production and NADPH oxidase activity in vascular systems.

  2007cited by this paper
• Nano-oncology: drug delivery, imaging, and sensing

  2006cited by this paper
• From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A).

  2006cited by this paper
• Redox behavior of tumor-inhibiting ruthenium(III) complexes and effects of physiological reductants on their binding to GMP.

  2006cited by this paper
• Fluorescence probes used for detection of reactive oxygen species.

  2005cited by this paper
• Polymers in Drug Delivery

  2004cited by this paper
• Nanoparticle and targeted systems for cancer therapy.

  2004cited by this paper
• Biodegradable nanoparticles for drug delivery and targeting

  2002cited by this paper
• Polymers in drug delivery.

  2001cited by this paper
• EPR and electrochemistry of [NH4]trans-[RuCl4(DMSO)(L)] complexes (L = DMSO, py ). X-ray molecular structure of [pyH][RuCl4(DMSO)(py)]

  2000cited by this paper
• Optimization of Preparation Techniques for Poly(Lactic Acid-Co-Glycolic Acid) Nanoparticles

  2000cited by this paper
• COLLOIDAL STABILITY AND DRUG INCORPORATION ASPECTS OF MICELLAR-LIKE PLA-PEG NANOPARTICLES

  1999cited by this paper
• Some aspects of the role of surfactants in the formation of nanoparticles

  1998cited by this paper
• Adv. Drug Delivery Rev.

  1997cited by this paper
• Synthesis, Characterization and Solution Chemistry of trans-Indazoliumtetrachlorobis(Indazole)Ruthenate(III), a New Anticancer Ruthenium Complex. IR, UV, NMR, HPLC Investigations and Antitumor Activity. Crystal Structures of trans-1-Methyl-Indazoliumtetrachlorobis-(1-Methylindazole)Ruthenate(III) an

  1996cited by this paper
• Nanocapsule formation by interfacial polymer deposition following solvent displacement

  1989cited by this paper

• Organic nanoplatforms for metallodrugs delivery: Current advances in colorectal cancer.

  2026cites this paper
• Development and evaluation of a Cu(II) complex as nanosuspension for enhanced antitumor efficacy against glioblastoma cancer

  2025cites this paper
• Recent advances in ruthenium (III) complex-loaded nanomaterial for enhanced cancer therapy efficacy

  2025cites this paper
• Revolutionizing anticancer treatment: Ruthenium-based nanoplatforms pave new paths

  2024cites this paper
• From the Discovery of Targets to Delivery Systems: How to Decipher and Improve the Metallodrugs’ Actions at a Molecular Level

  2023cites this paper
• Diruthenium(II-III)-ibuprofen-loaded chitosan-based microparticles and nanoparticles systems: encapsulation, characterisation, anticancer activity of the nanoformulations against U87MG human glioma cells

  2023cites this paper
• Poly(lactic acid)/β-cyclodextrin based nanoparticles bearing ruthenium(II)-arene naproxen complex: preparation and characterisation. Analytical validation for metal determination by microwave-induced plasma optical emission spectrometry

  2023cites this paper
• Photophysical Properties and DNA Binding of Two Intercalating Osmium Polypyridyl Complexes Showing Light-Switch Effects

  2022cites this paper
• Polymeric Nanosystems Applied for Metal-Based Drugs and Photosensitizers Delivery: The State of the Art and Recent Advancements

  2022influential citation
• Polymers and Small-Molecule Ru Species

  2021cites this paper
• Versatile delivery systems for non-platinum metal-based anticancer therapeutic agents

  2021cites this paper
• Effects of shell thickness of hollow poly(lactic acid) nanoparticles on sustained drug delivery for pharmacological treatment of glaucoma.

  2020cites this paper
• Polymer encapsulation of ruthenium complexes for biological and medicinal applications

  2019cites this paper
• Polymer "ruthenium-cyclopentadienyl" conjugates - New emerging anti-cancer drugs.

  2019cites this paper
• Pyridine Ruthenium(III) complexes entrapped in liposomes with enhanced cytotoxic properties in PC-3 prostate cancer cells

  2019cites this paper
• Synthesis and Characterization of FITC Labelled Ruthenium Dendrimer as a Prospective Anticancer Drug

  2019influential citation
• Anticancer Ruthenium(III) Complexes and Ru(III)-Containing Nanoformulations: An Update on the Mechanism of Action and Biological Activity

  2019cites this paper
• Synthesis of terpolymer-lipid encapsulated diruthenium(II,III)-anti-inflammatory metallodrug nanoparticles to enhance activity against glioblastoma cancer cells.

  2019cites this paper
• Nano-Based Systems and Biomacromolecules as Carriers for Metallodrugs in Anticancer Therapy

  2018cites this paper
• 111In-labelled polymeric nanoparticles incorporating a ruthenium-based radiosensitizer for EGFR-targeted combination therapy in oesophageal cancer cells

  2018cites this paper
• Nanoformulation as a Tool for Improve the Pharmacological Profile of Platinum and Ruthenium Anticancer Drugs

  2017cites this paper
• Ruthenium Anticancer Agents En Route to the Tumor

  2017cites this paper
• A systematic assessment of chemical, genetic, and epigenetic factors influencing the activity of anticancer drug KP1019 (FFC14A)

  2017cites this paper
• Designing of PLA scaffolds for bone tissue replacement fabricated by ordinary commercial 3D printer

  2017cites this paper
• Supramolecular Delivery Systems for Non-Platinum Metal-Based Anticancer Drugs.

  2017cites this paper
• Ruthenium complex exerts antineoplastic effects that are mediated by oxidative stress without inducing toxicity in Walker‐256 tumor‐bearing rats

  2017cites this paper
• Characterizing activation mechanisms and binding preferences of ruthenium metallo-prodrugs by a competitive binding assay.

  2017cites this paper
• Potencial antineoplásico do complexo de rutênio (RuC) em modelos tumorais in vitro e in vivo

  2017cites this paper
• Trends and Perspectives of Ruthenium Anticancer Compounds (Non‐PDT)

  2017cites this paper
• Ruthenium coordination compounds as drugs in modern anticancer therapy

  2016cites this paper
• Ru(III) anticancer agents with aromatic and non-aromatic dithiocarbamates as ligands: Loading into nanocarriers and preliminary biological studies.

  2016cites this paper
• Size-controlled synthesis of biodegradable nanocarriers for targeted and controlled cancer drug delivery using salting out cation

  2016cites this paper
• A dual-fluorescent nano-carrier for delivering photoactive ruthenium polypyridyl complexes.

  2016cites this paper
• Catalytic Radical Reduction in Aqueous Solution by a Ruthenium Hydride Intermediate.

  2016cites this paper
• Annals of Medicinal Chemistry and Research

  2015cites this paper
• Inorganic Compounds Going NANO

  2015cites this paper
• Role of mass spectrometry in the development and medicinal implementation of metal-based nanoparticles

  2015cites this paper
• Incorporating ruthenium into advanced drug delivery carriers – an innovative generation of chemotherapeutics

  2015cites this paper
• P(EO-co-LLA) functionalized Fe3O4@mSiO2 nanocomposites for thermo/pH responsive drug controlled release and hyperthermia.

  2014cites this paper